Erste Group Bank Issues Pessimistic Outlook for NVO Earnings

Novo Nordisk A/S (NYSE:NVO) – Stock analysts at Erste Group Bank decreased their FY2026 earnings estimates for shares of Novo Nordisk A/S in a research report issued to clients and investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $3.29 per share for the year, down from their previous estimate of $3.43. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.53 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S’s FY2027 earnings at $3.25 EPS.

A number of other brokerages also recently issued reports on NVO. Berenberg Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday. DZ Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $59.44.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $38.60 on Tuesday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company has a market cap of $172.36 billion, a price-to-earnings ratio of 9.44, a PEG ratio of 1.27 and a beta of 0.76. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. The business’s 50 day moving average price is $43.25 and its 200 day moving average price is $43.89.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a dividend of $0.5786 per share. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s dividend payout ratio is currently 20.05%.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership purchased a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $287,660,000. Maverick Capital Ltd. acquired a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $76,444,000. Public Employees Retirement System of Ohio purchased a new position in Novo Nordisk A/S in the 1st quarter valued at approximately $27,802,000. Rockefeller Capital Management L.P. increased its position in shares of Novo Nordisk A/S by 77.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,340,858 shares of the company’s stock worth $68,223,000 after acquiring an additional 584,275 shares during the period. Finally, Pictet Asset Management Holding SA acquired a new position in Novo Nordisk A/S during the 1st quarter worth $17,800,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.